Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Wallach Kildemoes, Helle ^a   Diderichsen, Finn ^a   Krasnik, Allan ^a   Lange, Theis ^a   Andersen, Morten ^b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Horizontal equity; Socioeconomic gradient; Statins to prevent cardiovascular disease; The high risk strategy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DENMARK; ECONOMICS; FEMALE; HEALTH CARE DISPARITY; HUMAN; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT; SOCIAL CLASS;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; DENMARK; FEMALE; HEALTHCARE DISPARITIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT; SOCIAL CLASS;

EID: 84866423588     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-610     Document Type: Article

References (76)

1. Explaining the social gradient in coronary heart disease: comparing relative and absolute risk approaches. Lynch J, Davey SG, Harper S, Bainbridge K, J Epidemiol Community Health 2006 60 5 436 441 10.1136/jech.2005.041350 16614335
2. Health inequalities among British civil servants: the Whitehall II study. Marmot MG, Smith GD, Stansfeld S, Patel C, North F, Head J, White I, Brunner E, Feeney A, Lancet 1991 337 8754 1387 1393 10.1016/0140-6736(91)93068-K 1674771
3. Socioeconomic inequalities in cardiovascular disease mortality; an international study. Mackenbach JP, Cavelaars AE, Kunst AE, Groenhof F, Eur Heart J 2000 21 14 1141 1151 10.1053/euhj.1999.1990 10924297
4. Widening socioeconomic inequalities in mortality in six Western European countries. Mackenbach JP, Bos V, Andersen O, Cardano M, Costa G, Harding S, Reid A, Hemstrom O, Valkonen T, Kunst AE, Int J Epidemiol 2003 32 5 830 837 10.1093/ije/dyg209 14559760
5. Trends in socioeconomic health differences between 1980-2005, Finland, Palosuo H, Koskinen S, Lahelma E, Kostiainen E, Prättälä R, Martelin T, Ostamo A, Keskimaki I, Sihto M, Linnanmäki E, 2009 http://www.stm.fi/c/document-library/get-file?folderId=39503&name=DLFE-8648. pdf 22218792
6. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT, Am J Epidemiol 1996 144 10 934 942 10.1093/oxfordjournals.aje.a008863 8916504
7. Magnitude and causes of socioeconomic differentials in mortality: further evidence from the Whitehall Study. Smith GD, Shipley MJ, Rose G, J Epidemiol Community Health 1990 44 4 265 270 10.1136/jech.44.4.265 2277246
8. The role of conventional risk factors in explaining social inequalities in coronary heart disease: the relative and absolute approaches to risk. Singh-Manoux A, Nabi H, Shipley M, Gueguen A, Sabia S, Dugravot A, Marmot M, Kivimaki M, Epidemiology 2008 19 4 599 605 10.1097/EDE.0b013e3181761cdc 18467960
9. Socioeconomic position and incidence of acute myocardial infarction: a meta-analysis. Manrique-Garcia E, Sidorchuk A, Hallqvist J, Moradi T, J Epidemiol Community Health 2011 65 4 301 309 10.1136/jech.2009.104075 20841371
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study group, Lancet 1994 344 8934 1383 1389 7968073
11. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. Ong HT, QJM 2005 98 8 599 614 10.1093/qjmed/hci093 16006501
12. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, Eur Heart J 2003 24 11 987 1003 10.1016/S0195-668X(03)00114-3 12788299
13. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, Ardal S, Alter DA, Laupacis A, BMJ 2006 332 7555 1419 10.1136/bmj.38849.487546.DE 16737980
14. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. McElduff P, Jaefarnezhad M, Durrington PN, Heart 2006 92 9 1213 1218 10.1136/hrt.2005.085183 16717068
15. Strandberg-Larsen M, Nielsen M, Vallgårda S, Krasnik A, Vrangbæk K, Health system review Health Systems in Transition: World Health Organisation, Denmark, Mossialos E, 2007 9(6)
16. Donaldson C, Gerard K, Economics of health care financing: The visible hand Macmillan Press Ltd., London 1 1993
17. Pricing and reimbursement of drugs in Denmark. Pedersen KM, Eur J Health Econom 2003 4 460 465
18. Equity in the delivery of health care in Europe and the US. van DE, Wagstaff A, der BH v, Christiansen T, De GD, Duchesne I, Gerdtham UG, Gerfin M, Geurts J, Gross L, Hakkinen U, John J, Klavus J, Leu RE, Nolan B, ODonnell O, Propper C, Puffer F, Schellhorn M, Sundberg G, Winkelhake O, J Health Econ 2000 19 5 553 583 10.1016/S0167-6296(00)00050-3 11184794
19. Explaining income-related inequalities in doctor utilisation in Europe. van Doorslaer E, Koolman X, Jones AM, Health Econ 2004 13 7 629 647 10.1002/hec.919 15259043
20. Measuring and testing for inequity in the delivery of health care. Wagstaff A, van Doorslaer E, J Hum Resour 2000 35 4 716 733 10.2307/146369
21. Persistent socio-economic differences in revascularization after acute myocardial infarction despite a universal health care system-a Danish study. Rasmussen JN, Rasmussen S, Gislason GH, Abildstrom SZ, Schramm TK, Torp-Pedersen C, Kober L, Diderichsen F, Osler M, Madsen M, Cardiovasc Drugs Ther 2007 21 6 449 457 10.1007/s10557-007-6058-7 17955357
22. Income related inequality in prescription drugs in Denmark. Gundgaard J, Pharmacoepidemiol Drug Saf 2005 14 5 307 317 10.1002/pds.1039 15508133
23. Use of statins and beta-blockers after acute myocardial infarction according to income and education. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Kober L, Diderichsen F, Osler M, Torp-Pedersen C, Madsen M, J Epidemiol Community Health 2007 61 12 1091 1097 10.1136/jech.2006. 055525 18000133
24. Income-related inequality in utilization of health services in Denmark: Evidence from Funen County. Gundgaard J, Scand J Public Health 2006 34 5 462 471 10.1080/14034940600554644 16990156
25. The sustainability of European health care systems: beyond income and aging. Pammolli F, Riccaboni M, Magazzini L, Eur J Health Econ 2011 E-pub ahead of print
26. An evidence-based policy prescription for an aging population. Chappell NL, Hollander MJ, Healthc Pap 2011 11 1 8 18 21464622
27. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J, BMJ 2005 331 7516 551 10.1136/bmj.38555.648623.8F 16103030
28. A systematic review and economic evaluation of statins for the prevention of coronary events. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N, Health Technol Assess 2007 11 14 1 160 17927921
29. Primary prevention of cardiovascular diseases. Sigurdsson EL, Thorgeirsson G, Scand J Prim Health Care 2003 21 2 68 74 10.1080/ 02813430310000717 12877367
30. Rose G, The strategy of preventive medicine Oxford University Press, Oxford, New York, Tokyo 1992
31. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S, Eur Heart J 2004 25 6 484 491 10.1016/j.ehj.2003.11.012 15039128
32. Revisiting Rose: strategies for reducing coronary heart disease. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, Mustard CA, BMJ 2006 332 7542 659 662 10.1136/bmj.332.7542.659 16543339
33. Closing the gap in a generation: health equity through action on the social determinants of health. Marmot M, Friel S, Bell R, Houweling TA, Taylor S, Lancet 2008 372 9650 1661 1669 10.1016/S0140-6736(08)61690-6 18994664
34. Social inclusion and the European Union. Atkinson T, Journal of Common Market Studies 2002 40 4 625 643 10.1111/1468-5965.00391
35. Will cardiovascular disease prevention widen health inequalities? Capewell S, Graham H, PLoS Med 2010 7 8 1000320 10.1371/journal.pmed.1000320 20811492
36. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Tunstall-Pedoe H, Woodward M, Heart 2006 92 3 307 310 16166099
37. Regional variation in the prescribing for diabetes and use of secondary preventative therapies in Ireland. Usher C, Bennett K, Feely J, Pharmacoepidemiol Drug Saf 2005 14 8 537 544 10.1002/pds.1104 15818637
38. How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England. Ward PR, Noyce PR, St Leger AS, Int J Equity Health 2007 6 2 10.1186/1475-9276-6-2 17386118
39. Is the physicians adherence to prescription guidelines associated with the patients socio-economic position? An analysis of statin prescription in South Sweden. Ohlsson H, Lynch K, Merlo J, J Epidemiol Community Health 2010 64 8 678 683 10.1136/jech.2008.081166 19692716
40. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A, Br J Clin Pharmacol 2009 67 3 355 362 10.1111/j.1365-2125.2008.03360.x 19523016
41. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Reid FD, Cook DG, Whincup PH, Heart 2002 88 1 15 19 10.1136/heart.88.1.15 12067933
42. Differences in income-related inequality and horizontal inequity in ambulatory care use between rural and non-rural areas: using the 1998-2001 U.S. National Health Interview Survey data. Shin H, Kim J, Int J Equity Health 2010 9 17 10.1186/1475-9276-9-17 20598133
43. The Danish National Prescription Registry. Kildemoes HW, Sorensen HT, Hallas J, Scand J Public Health 2011 39 Supple 7 38 41 21775349
44. WHO Collaborating centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2010 Norwegian Institute of Public Health, Oslo 2010
45. Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Wallach Kildemoes H, Hendriksen C, Andersen M, Pharmacoepidemiol Drug Saf 2011 10.1002/pds.2195
46. Measuring the magnitude of socio-economic inequalities in health: an overview of available measures illustrated with two examples from Europe. Mackenbach JP, Kunst AE, Soc Sci Med 1997 44 6 757 771 10.1016/S0277-9536(96) 00073-1 9080560
47. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M, J Clin Epidemiol 2003 56 2 124 130 10.1016/S0895-4356(02)00591-7 12654406
48. Nonparametric Estimates of Standard Error-the Jackknife, the Bootstrap and Other Methods. Efron B, Biometrika 1981 68 3 589 599 10.1093/biomet/68.3.589
49. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Woodward M, Brindle P, Tunstall-Pedoe H, Heart 2007 93 2 172 176 17090561
50. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P, BMJ 2008 336 7659 1475 1482 10.1136/bmj.39609.449676.25 18573856
51. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Thomsen TF, McGee D, Davidsen M, Jorgensen T, Int J Epidemiol 2002 31 4 817 822 10.1093/ije/31.4.817 12177028
52. Statin prescription in men and women at cardiovascular risk: to whom and when? Brugts JJ, Deckers JW, Curr Opin Cardiol 2010 25 4 484 489 20625281
53. Individual survival time prediction using statistical models. Henderson R, Keiding N, J Med Ethics 2005 31 12 703 706 10.1136/jme.2005.012427 16319233
54. The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. Law MR, Wald NJ, Morris JK, J Med Screen 2004 11 1 3 7 10.1258/096914104772950673 15006106
55. Sick individuals and sick populations. Rose G, Int J Epidemiol 1985 14 1 32 38 10.1093/ije/14.1.32 3872850
56. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Diederichsen AC, Sand NP, Norgaard B, Lambrechtsen J, Jensen JM, Munkholm H, Aziz A, Gerke O, Egstrup K, Larsen ML, Petersen H, Hoilund-Carlsen PF, Mickley H, Eur J Prev Cardiol 2012 19 3 558 564 10.1177/1741826711409172 21525124
57. Individual social class, area-based deprivation, cardiovascular disease risk factors, and mortality: the Renfrew and Paisley Study. Smith GD, Hart C, Watt G, Hole D, Hawthorne V, J Epidemiol Community Health 1998 52 6 399 405 10.1136/jech.52.6.399 9764262
58. Metabolic and lifestyle predictors of ischemic heart disease and all-cause mortality among normal weight, overweight, and obese men: a 16-year follow-up in the Copenhagen Male Study. Suadicani P, Hein HO, von Eyben FE, Gyntelberg F, Metab Syndr Relat Disord 2009 7 2 97 104 10.1089/met.2008.0041 19032035
59. Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications. Dominguez H, Schramm TK, Norgaard ML, Abildstrom SZ, Kober L, Jorgensen C, Guterbaum TJ, Poulsen HE, Torp-Pedersen C, Gislason GH, Open Cardiovasc Med J 2009 3 152 159 10.2174/1874192400903010152 20016749
60. Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study. Forde I, Chandola T, Raine R, Marmot MG, Kivimaki M, Atherosclerosis 2011 215 1 223 228 10.1016/j.atherosclerosis.2010.12.012 21227420
61. Statin prescribing in Australia: socioeconomic and sex differences. A cross-sectional study. Stocks NP, Ryan P, McElroy H, Allan J, Med J Aust 2004 180 5 229 231 14984343
62. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH, Am J Epidemiol 2007 166 3 348 354 10.1093/aje/kwm070 17504779
63. Socioeconomic variation in participation in colorectal cancer screening. McCaffery K, Wardle J, Nadel M, Atkin W, J Med Screen 2002 9 3 104 108 10.1136/jms.9.3.104 12370320
64. Psychosocial Determinants of Socioeconomic Inequalities in Cancer Screening Participation: A Conceptual Framework. von Wagner C, Good A, Whitaker KL, Wardle J, Epidemiol Rev 2011 33 1 135 147 10.1093/epirev/mxq018 21586673
65. Will screening individuals at high risk of cardiovascular events deliver large benefits? Capewell S, No. BMJ 2008 337 1395 10.1136/bmj.a1395
66. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J, Eur J Clin Pharmacol 2005 61 9 667 674 10.1007/s00228-005-0980-z 16151763
67. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Golomb BA, Evans MA, Am J Cardiovasc Drugs 2008 8 6 373 418 10.2165/0129784-200808060-00004 19159124
68. Non-adherence to statin therapy: a major challenge for preventive cardiology. Bates TR, Connaughton VM, Watts GF, Expert Opin Pharmacother 2009 10 18 2973 2985 10.1517/14656560903376186 19954271
69. Medication adherence trends with statins. Huser MA, Evans TS, Berger V, Adv Ther 2005 22 2 163 171 10.1007/BF02849887 16020406
70. The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. Lindman AS, Veierod MB, Pedersen JI, Tverdal A, Njolstad I, Selmer R, Eur J Cardiovasc Prev Rehabil 2007 14 4 501 507 10.1097/HJR.0b013e328011490a 17667638
71. How should we balance individual and population benefits of statins for preventing cardiovascular disease? Hingorani AD, Hemingway H, BMJ 2011 342 6244
72. Targeted case finding for cardiovascular prevention. Marshall T, BMJ 2010 340 1376 10.1136/bmj.c1376 20418544
73. The polypill in the primary prevention of cardiovascular disease. Wald DS, Wald NJ, Fundam Clin Pharmacol 2010 24 1 29 35 10.1111/j.1472-8206.2009. 00795.x 20002198
74. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (polypill) on cardiovascular risk factors. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, Rastegarpanah M, Khoshnia M, Semnani S, Salahi R, Thomas GN, Larijani B, Cheng KK, Malekzadeh R, Int J Clin Pract 2010 64 9 1220 1227 10.1111/j.1742-1241.2010. 02412.x 20653798
75. Vos T, Carter R, Barendregt J, Mihalopoulos C, Veerman J, Magnus A, Cobiac L, Bertram M, Wallace A, Assessing cost-effectiveness in prevention (ACE-Prevntion): Final report University of Queensland, Brisbane and Deakin University, Melbourne 2010 http://www.sph.uq.edu.au/bodce-ace-prevention
76. Diderichsen F, Andersen I, Manual C, Health inequalities-determinants and policies University of Copenhagen & Danish Ministry of Health, Copenhagen 2011 http://www.sst.dk/∼/media/English/ Health%20promotion%20and%20disease%20prevention/International/ Health%20Inequality%20-%20determinants%20and%20policies.ashx\